

JAN 05 2007

Attorney Docket No. 1760.1001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

3	PART .		
=	In re Patent Applic	cation of:	
	Shigeo YAGUCHI		
	Application No.: 1	10/748,234	Group Art Unit: 3734
	Confirmation No.	7113	
	Filed: December	31, 2003	Examiner: Vy Q. Bui
	For: INTRAOC	ULAR DEVICE FOR RETAININ	G A LENS CAPSULE
		INFORMATION DISCL	DSURE STATEMENT
	Commissioner for PO Box 1450 Alexandria, VA 22		
	Sir:		
	provided certain in subject U.S. pater	nformation which the Examiner i	provisions of 37 CFR § 1.56, there is hereby may consider material to the examination of the at the Examiner make this information of record subject application.
	1. Enclosures	s accompanying this Information	Disclosure Statement are:
	1a. ⊠ 1b. ⊠ 1c. ⊠	publications.	pt for U.S. Patents and U.S. Patent Application ommunication(s) from a foreign Patent Office
	1d. ⊠	or a PCT International Search English language translation	
	1e. 🗌 1f. 📋 1g. 🗍	Explanations of Relevancy of providing a concise explanati List of Copending Application	References (ATTACHMENT 1(e), hereto) for on of non-English publications. s (ATTACHMENT 1(f), hereto). Occuments (ATTACHMENT 1(g), hereto).
	2. X This Info	ormation Disclosure Statement is	s filed under 37 CFR § 1.97(b): 2a or 2b or 2c or 2d)
	2a. 🗌 2b. 🔲	Within three months of the fil	ing date of a national application; ate of entry of the national stage as set forth in
	2c. ⊠ 2d. ☐	Before the mailing of a first C	ffice Action on the merits; or ffice Action after the filing of a Request for

Serial No.: 10/748,234

3.	specified Action un closes pr	rmation Disclosure Statement is filed under 37 CFR § 1.97(c) after the period in paragraph 2 above but before the mailing date of any of a Final Office der § 1.113, a Notice of Allowance under § 1.311 or an action that otherwise osecution in the application, AND (Check either Item 3a or 3b; Item 3b to be checked if any reference known for more than 3 months)
	3a. ∐ 3b. ☐	The § 1.97(e) Statement in Item 5 below is applicable; OR The \$180.00 fee set forth in 37 CFR § 1.17(p) is: enclosed.
		to be charged to Deposit Account No. 19-3935.
4.		mation Disclosure Statement is filed under 37 CFR § 1.97(d) after the period in paragraph 3 above, but on or before payment of the Issue Fee, AND
	4a.	The § 1.97(e) Statement in Item 5 below is applicable; AND The \$180.00 fee set forth in 37 CFR § 1.17(p) is: ———————————————————————————————————
		to be charged to Deposit Account No. 19-3935.
5.	Statemen	t under § 1.97(e) (applicable if Item 3a or Item 4a is checked) (Check either Item 5a or 5b)
	5a. 🗌	In accordance with 37 CFR § 1.97(e)(1), it is stated that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
	5b.	In accordance with 37 CFR § 1.97(e)(2), it is stated that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known by any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
6.	This is a (1.53(b).	continuation/divisional/continuation-in-part application under 37 CFR §
•		(Check appropriate Items 6a and/or 6b)
	6a. 🗌	Copies of the publications listed on the attached Form PTO-1449 which were previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, have been omitted pursuant to 37 CFR § 1.98(d).
	6b. 🗌	Copies of the publications listed on the attached Form PTO-1449 which were not previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. & 120, are provided berewith

Serial No.: 10/748,234

7.		This is a Request for Continued Examination under 37 CFR § 1.114. (Check either Item 7a or 7b)						
		7a. 7b.	The Issue Fee has not been paid. A Petition to Withdraw from issue under 37 CFR § 1.313(c) is filed concurrently herewith or has been granted. A Request for Continued Examination under 37 CFR § 1.114, after payment of the Issue Fee, is proper in accordance with 37 CFR § 1.114(a), respectively.					
8.		This is	a Supplemental Information Disclosure Statement. (Check either Item 8a or 8b)					
		8a. 🗌	1.97(f) supplements the Information Disclosure Statement filed on A bona fide attempt was made to comply with 37 CFR § 1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental IDS can					
		8b. 🗌	be considered as if properly filed on This Supplemental Information Disclosure Statement is timely filed within one (1) month of the Notice under 37 CFR §§ 1.97 and 1.98, mailed					
9.	⊠ lr u	n accord ndersto	ance with 37 CFR § 1.98, a concise explanation of what is presently od to be the relevance of each non-English language publication is: (Check appropriate Items 9a, 9b, 9c and/or 9d)					
		9a. 🛚	satisfied for the non-English language publication(s) cited on the enclosed "English language version of the search report or action which indicates the degree of relevance found by the foreign office". (See MPEP § 609, Minimum Requirements for an Information Disclosure Statement, Part A(3): Concise Explanation of Relevance, 8th Ed., Rev. 2)					
		9b. ☐ 9c. ☒	attached Form PTO-1449 as having an English language translation					
		9d. 🗌	(complete or relevant portion(s)) attached thereto. enclosed as Attachment 1(e), hereto.					
10.	be se	e, materi arch rep	sion is made that the information cited in this Statement is, or is considered to all to patentability nor a representation that a search has been made (other than port(s) from a counterpart foreign application or a PCT International Search submitted herewith). 37 CFR §§ 1.97(a) and (h).					

Serial No.: 10/748,234

11. The Commissioner is authorized to credit any overpayment or charge any additional fee required under 37 CFR § 1.17 for this Information Disclosure Statement to Deposit Account No. 19-3935.

Respectfully submitted,

STAAS & HALSEY LLP

Dated: (/5/U/ 1201 New York Ave., N.W., 7th Floor

Washington, D.C. 20005 Telephone: (202) 434-1500 Facsimile: (202) 434-1501 By: William F. Herbert

Registration No. 31,024



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE

PATENT AND TRADEMARK OFFICE

Sheet 1 of 1 APPLICATION NO. ATTORNEY DOCKET NO. 1760.1001 10/748,234 FIRST NAMED INVENTOR Shigeo YAGUCHI

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

FILING DATE GROUP ART UNIT December 31, 2003 3734

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
/VB/	AA	5,807,244	9/15/98	Barot			
/VB/	AB	5,843,184	12/1/98	Cionni			
/VB/	AC	6,183,480*	2/6/01	Mackool		·	
	AD						

^{*} Already of record

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	TRANSL/ YES	ATION NO	ABSTRACT
/VB/	AE	10-80441	3/31/98	Japan	Х		
/VB/	AF	2002-95691	4/2/02	Japan	Х		
/VB/	AG	10-80441 (As amended and re-published)	10/9/01	Japan	х		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)					
/VB/	АН	Japanese Office Action mailed April 18, 2006 in corresponding Japanese Patent Application No. 2003-172646.	х		
/VB/	Al	Japanese Office Action mailed August 22, 2006 in corresponding Japanese Patent Application No. 2003-172646.	х		
/VB/	AJ	"Capsular stabilization device to preserve lens capsule integrity during phacoemulsification with a weak zonule", Nishimura et al., J. Cataract Refract Surgery, 2006, 32:392-395.			
:	LA				

EXAMINER	DATE CONSIDERED
/Vy Bui/	12/26/2007